341 related articles for article (PubMed ID: 24187403)
21. [Tubulointerstitial nephritis antigen expression in chronic kidney disease and its clinical significance].
Yang Y; Xiao L; Xu X; Yang D; Zhu X; Hu P; Sun L
Zhonghua Yi Xue Za Zhi; 2014 Jan; 94(4):246-50. PubMed ID: 24731487
[TBL] [Abstract][Full Text] [Related]
22. Increased chemokine excretion in patients suffering from chronic kidney disease.
Lebherz-Eichinger D; Klaus DA; Reiter T; Hörl WH; Haas M; Ankersmit HJ; Krenn CG; Roth GA
Transl Res; 2014 Dec; 164(6):433-43.e1-2. PubMed ID: 25168017
[TBL] [Abstract][Full Text] [Related]
23. Renal handling of zinc in chronic kidney disease patients and the role of circulating zinc levels in renal function decline.
Damianaki K; Lourenco JM; Braconnier P; Ghobril JP; Devuyst O; Burnier M; Lenglet S; Augsburger M; Thomas A; Pruijm M
Nephrol Dial Transplant; 2020 Jul; 35(7):1163-1170. PubMed ID: 31006015
[TBL] [Abstract][Full Text] [Related]
24. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
25. Comparisons of serum vitamin D levels, status, and determinants in populations with and without chronic kidney disease not requiring renal dialysis: a 24-hour urine collection population-based study.
Guessous I; McClellan W; Kleinbaum D; Vaccarino V; Zoller O; Theler JM; Paccaud F; Burnier M; Bochud M;
J Ren Nutr; 2014 Sep; 24(5):303-12. PubMed ID: 25030223
[TBL] [Abstract][Full Text] [Related]
26. Diabetes modifies effect of high-phosphate diet on fibroblast growth factor-23 in chronic kidney disease.
Muras K; Masajtis-Zagajewska A; Nowicki M
J Clin Endocrinol Metab; 2013 Dec; 98(12):E1901-8. PubMed ID: 24092829
[TBL] [Abstract][Full Text] [Related]
27. Cardiovascular and renal outcome in subjects with K/DOQI stage 1-3 chronic kidney disease: the importance of urinary albumin excretion.
Brantsma AH; Bakker SJ; Hillege HL; de Zeeuw D; de Jong PE; Gansevoort RT;
Nephrol Dial Transplant; 2008 Dec; 23(12):3851-8. PubMed ID: 18641082
[TBL] [Abstract][Full Text] [Related]
28. Sclerostin as a new key factor in vascular calcification in chronic kidney disease stages 3 and 4.
Lv W; Guan L; Zhang Y; Yu S; Cao B; Ji Y
Int Urol Nephrol; 2016 Dec; 48(12):2043-2050. PubMed ID: 27465794
[TBL] [Abstract][Full Text] [Related]
29. Is serum sclerostin a marker of atherosclerosis in patients with chronic kidney disease-mineral and bone disorder?
Figurek A; Spasovski G
Int Urol Nephrol; 2018 Oct; 50(10):1863-1870. PubMed ID: 30030677
[TBL] [Abstract][Full Text] [Related]
30. Low serum bilirubin concentration is a predictor of chronic kidney disease.
Tanaka M; Fukui M; Okada H; Senmaru T; Asano M; Akabame S; Yamazaki M; Tomiyasu K; Oda Y; Hasegawa G; Toda H; Nakamura N
Atherosclerosis; 2014 Jun; 234(2):421-5. PubMed ID: 24763407
[TBL] [Abstract][Full Text] [Related]
31. Association between Urine Ammonium and Urine TGF-
Raphael KL; Gilligan S; Hostetter TH; Greene T; Beddhu S
Clin J Am Soc Nephrol; 2018 Feb; 13(2):223-230. PubMed ID: 29146699
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of different urinary uric acid indicators in patients with chronic kidney disease.
Guan H; Zheng Y; Zhou X; Xu Y; Fu C; Xiao J; Ye Z
BMC Nephrol; 2020 Jul; 21(1):290. PubMed ID: 32698778
[TBL] [Abstract][Full Text] [Related]
33. Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults.
Amrein K; Amrein S; Drexler C; Dimai HP; Dobnig H; Pfeifer K; Tomaschitz A; Pieber TR; Fahrleitner-Pammer A
J Clin Endocrinol Metab; 2012 Jan; 97(1):148-54. PubMed ID: 21994959
[TBL] [Abstract][Full Text] [Related]
34. Circulating Levels of Dickkopf-Related Protein 1 Decrease as Measured GFR Declines and Are Associated with PTH Levels.
Forster CM; White CA; Turner ME; Norman PA; Ward EC; Hopman WM; Adams MA; Holden RM
Am J Nephrol; 2020; 51(11):871-880. PubMed ID: 33238271
[TBL] [Abstract][Full Text] [Related]
35. Serum surfactant protein D is associated with the prognosis in patients with chronic kidney disease.
Xie F; Wang X; Ding Z; Fan P; Fan L; Chen Z; Ma G
J Cardiovasc Med (Hagerstown); 2013 Jun; 14(6):461-5. PubMed ID: 23314596
[TBL] [Abstract][Full Text] [Related]
36. Can we compare serum sclerostin results obtained with different assays in hemodialysis patients?
Moysés RM; Jamal SA; Graciolli FG; dos Reis LM; Elias RM
Int Urol Nephrol; 2015 May; 47(5):847-50. PubMed ID: 25862239
[TBL] [Abstract][Full Text] [Related]
37. Increased urinary osmolyte excretion indicates chronic kidney disease severity and progression rate.
Gil RB; Ortiz A; Sanchez-Niño MD; Markoska K; Schepers E; Vanholder R; Glorieux G; Schmitt-Kopplin P; Heinzmann SS
Nephrol Dial Transplant; 2018 Dec; 33(12):2156-2164. PubMed ID: 29554320
[TBL] [Abstract][Full Text] [Related]
38. Clinical and endocrine correlates of circulating sclerostin levels in patients with type 1 diabetes mellitus.
Neumann T; Hofbauer LC; Rauner M; Lodes S; Kästner B; Franke S; Kiehntopf M; Lehmann T; Müller UA; Wolf G; Hamann C; Sämann A
Clin Endocrinol (Oxf); 2014 May; 80(5):649-55. PubMed ID: 24237244
[TBL] [Abstract][Full Text] [Related]
39. Investigating FGF-23 concentrations and its relationship with declining renal function in paediatric patients with pre-dialysis CKD Stages 3-5.
Sinha MD; Turner C; Dalton RN; Rasmussen P; Waller S; Booth CJ; Goldsmith DJ
Nephrol Dial Transplant; 2012 Dec; 27(12):4361-8. PubMed ID: 22529162
[TBL] [Abstract][Full Text] [Related]
40. Circulating α-klotho levels in CKD and relationship to progression.
Kim HR; Nam BY; Kim DW; Kang MW; Han JH; Lee MJ; Shin DH; Doh FM; Koo HM; Ko KI; Kim CH; Oh HJ; Yoo TH; Kang SW; Han DS; Han SH
Am J Kidney Dis; 2013 Jun; 61(6):899-909. PubMed ID: 23540260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
